NovoRapid[®] FlexTouch[®] — insulin delivery with a twist, touch, and click



Pull off the pen cap.



Pull off paper tab from the needle and dispose of it.



Attach the needle straight and tightly onto NovoRapid[®] FlexTouch[®]. NovoRapid[®] FlexTouch[®] is designed for use with both NovoTwist[®] and NovoFine[®] needles.

Pull off the big outer needle cap and keep it for later.

Pull off the inner needle cap and dispose of it.



To prime the pen, turn the dose selector to select 2 units.





the needle pointing upwards and tap the cartridge gently.



Touch and hold down the pushbutton. A drop of insulin should appear at the needle tip. If not, repeat the procedure up to 6 times. If insulin does not appear, change the needle and repeat once more. If a drop of insulin still does not appear, the pen is defective and you must use a new pen.





Inject the dose by touching and holding the push-button until the dose selector returns to zero.

Turn the dose selector to select the

number of units you need to inject.



When dial returns to zero, an endof-dose click confirms delivery.

The needle must remain under the skin for at least 6 seconds following this confirmation.



Remove the needle from the skin.



Place the big outer needle cap on a flat surface, and, without touching it or the needle, guide the pen into the cap until the needle is covered.

Then push the cap onto the pen until it is secure.

Remove the needle and dispose of it as directed by your healthcare professional.

Store NovoRapid[®] FlexTouch[®] without the needle attached and put the pen cap back on after every use. Store NovoRapid[®] FlexTouch[®] at room temperature until your next injection.

NovoRapid® (insulin aspart) is indicated for treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. It should normally be used in regimens together with an intermediate or long-acting insulin. NovoRapid® (10 mL vials) may also be used for continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for insulin infusion. Please refer to the NovoRapid® Consumer Information for a complete list of contraindications, warnings and precautions, adverse reactions and dosing. Date of preparation: September 2013



All trademarks owned by Novo Nordisk A/S and used by Novo Nordisk Canada Inc. Novo Nordisk Canada Inc., 300-2680 Skymark Avenue, Mississauga, Ontario L4W 5L6. Tel: (905) 629-4222 or 1-800-465-4334, www.novonordisk.ca © 09/2013 Novo Nordisk Canada Inc.



